Journal
CEREBROVASCULAR DISEASES
Volume 51, Issue 6, Pages 697-705Publisher
KARGER
DOI: 10.1159/000524414
Keywords
Ischemic stroke; Endothelial progenitor cells; Novel drug therapy
Categories
Funding
- Zhejiang provincial basic public welfare research program [LGF21H200007]
- Major horizontal projects of Zhejiang Shuren University [202111842040]
Ask authors/readers for more resources
EPCs, as newly discovered stem cells, play a crucial role in promoting angiogenesis in ischemic tissue, repairing damaged vascular endothelium, and maintaining vascular homeostasis.
Background: Ischemic stroke, a common central nervous system disease that seriously threatens human life and health, is characterized by rapid progress and a high disability fatality rate. Ischemic tissue can produce a large amount of vascular endothelial growth factor (VEGF) and stromal cell-derived factor 1 (SDF-1) to promote the mobilization of endothelial progenitor cells (EPCs). Summary: As newly discovered stem cells, EPCs can promote angiogenesis in ischemic tissue, repair the damaged vascular endothelium, and maintain vascular homeostasis. Thus, EPCs have become a new research hotspot in this field. This review focuses on the mechanism of EPCs and the intervention of various novel drugs, including small molecules and biomolecules, which will promote the capture, proliferation, and differentiation of EPCs. Then, we explore the promotion of vascular health and the prospect of its application in the treatment of cerebral ischemic stroke (CIS). Key Message: It is clinically significant to study the potential of new drug therapy to target EPCs. More effective cytokines, signal pathways, and other drugs should be explored in the future and their specific mechanisms determined. Research should reveal more biological functions of EPCs and achieve their efficient amplification to improve therapy against CIS stroke.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available